Jakarta –
The Ministry of Agriculture through the Agricultural Research and Development Agency (Balitbangtan) together with the Indonesian Doctors Association (IDI) developed eucalyptus products as Corona antivirals. This collaboration received appreciation from the General Chairperson of the Indonesian Doctors Association (PB IDI) Daeng M Faqih. According to Daeng, his party will support all existing innovation and research efforts.
“I think eucalyptus research is an example of encouraging good research innovation in Indonesia,” said Daeng in a written statement, Friday (7/5/2021).
Daeng considered that the results of the research carried out were extraordinary and showed very good progress. Therefore, he requested that all IDI ranks provide space for researchers and doctors conducting clinical trials to disseminate the results of their research.
“In the future, doctors throughout Indonesia understand that this research has been carried out according to procedures,” he said.
Meanwhile, the Herbal Medicine Expert from the Faculty of Medicine, University of Indonesia (UI), Purwantyastuti also gave high appreciation for the efforts to research Indonesian plants in the midst of a pandemic.
“I really appreciate this research. Of course, one year of hard work has finally paid off very well to clinical trials,” he said.
Purwantyastuti hopes that all the research results of the nation’s children can be of benefit to both the people of Indonesia and the world. That way, native Indonesian herbal plants can be increasingly global and glimpsed by the western world.
“It is hoped that the next trip we are waiting for other clinical trials with more subjects in multicenter and the important thing is to choose the best research objectives, so that it can be directly proven and can be claimed benefits,” he concluded.
On the other hand, Dr. Arif Santoso from the Faculty of Medicine, Hasanuddin University explained that when clinical trials using eucalyptus gave significant results in COVID-19 patients. This can be seen with the significant increase in CT value in the realtime PCR test, as a representation of the decrease in viral load in the treatment group compared to the control group. The proportion of negative COVID-19 in the treatment group also increased significantly.
In addition, the eucalyptus formulation of Balitbangtan significantly decreased proinflammatory cytokines (IL-6), increased lymphocyte proliferation, and decreased NLR without increasing TGFb1.
Furthermore, the results of the IRCVS research conducted at the Biosafety Level 3 / BSL-3 Laboratory by paying attention to maximum biorisk and biosafety, in general, have shown that the single ingredient and the eucalyptus formula of Balitbangtan tested can reduce the number of particles and the viability of the SARS-CoV 2 virus, as well as reduce cell damage due to SARS-CoV-2 infection. Likewise with the toxicity test which gave good results.
(prf / ega)
– .
